

# Joao V Alessi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6258548/publications.pdf>

Version: 2024-02-01

12  
papers

546  
citations

1478505

6  
h-index

1720034

7  
g-index

12  
all docs

12  
docs citations

12  
times ranked

410  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	1.1	151
2	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	7.1	117
3	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
4	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1176-1187.	1.1	49
5	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. , 2021, 9, e003536.		45
6	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
7	Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1761-1769.	6.3	27
8	Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1640-1650.	7.0	19
9	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
10	Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series. <i>Lung Cancer</i> , 2020, 139, 9-12.	2.0	12
11	Immunotherapy in lung cancer: effective for patients with poor performance status?. <i>Lancet Respiratory Medicine</i> , 2020, 8, 838-839.	10.7	5
12	Response to Hopkins, Kichenadasse, Logan, et al. <i>Journal of the National Cancer Institute</i> , 2021, , .	6.3	0